Yahoo · Nov 14, 2026
Pfizer (PFE) Secures $1.5 Billion For Berobenatide Development
Pfizer (NYSE:PFE) announced a partnership with Blackstone Life Sciences to co-fund late stage development of berobenatide, its GLP-1 obesity drug candidate. The arrangement provides up to $1.5b in development funding for berobenatide, focused on chronic weight management and obesity related conditions. Pfizer keeps full operational control of berobenatide, while Blackstone Life Sciences receives milestone based economics linked to the program's progress. This berobenatide funding deal with...


